View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 16, 2022

Velocity makes three tech invests to boost clinical trial engagement

In one investment, Velocity acquires TrierHealth, a secure platform that permits digital clinical trial execution.

Velocity Clinical Research has made three investments in technology to extend patient community, boost client engagement in trials, and expedite the development of therapies in its 30 integrated locations.

The company randomised 25,000 subjects into Phase II and III clinical trials in the US in the last 12 months.

Investing in technology will aid Velocity to identify patients and enhance the participation frequency in trials.

Initially, Velocity collaborated with Advarra on a regulatory and compliance technology rollout. 

This partnership leverages Advarra’s Clinical Conductor Enterprise-level clinical trial management system (CTMS) integrated with eReg and eSource, for accessing more than 500,000 patients’ data in its national site network.

Under the second investment, Master Control will offer its Quality Management System (QMS). 

With the development, patients and sponsor partners of Velocity will profit from its improved expertise to back new innovations, enhance quality and compliance and facilitate improved site efficiency attained using automated quality processes. 

Furthermore, the company acquired a secure platform called TrierHealth that permits digital clinical trial execution.

The research and development (R&D) team of TrierHealth works in the Indian city of Hyderabad for developing patient-centred technology that leverages artificial intelligence and data science to boost clinical research. 

With the latest development, TrierHealth founder Raghu Punnamraju will join Velocity as chief technology officer.

Velocity Clinical Research chief executive and president Dr G Paul Evans said, “We’re building a global community of patients who are engaged, advocate for participation in clinical research, and actively take part in multiple studies. 

“Velocity is setting a new standard of integration for the research site industry to better recruit and retain patients into clinical research.”

In April last year, Global Healthcare Opportunities (GHO Capital) entered an agreement for the acquisition of Velocity Clinical Research.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy